{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:41:55Z","timestamp":1790707315705,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.intimp.2025.114268","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:12:18Z","timestamp":1740125538000},"page":"114268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis"],"prefix":"10.1016","volume":"151","author":[{"given":"Jingjing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingmin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114268_b0005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-020-01944-5","article-title":"A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia","volume":"98","author":"Kirtonia","year":"2020","journal-title":"J. Mol. Med. (Berlin)"},{"key":"10.1016\/j.intimp.2025.114268_b0010","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and challenges in the treatment of AML","volume":"44","author":"Abaza","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.intimp.2025.114268_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.intimp.2025.114268_b0020","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.clml.2019.11.017","article-title":"Response kinetics and clinical benefits of nonintensive AML therapies in the absence of morphologic response","volume":"20","author":"Stein","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.intimp.2025.114268_b0025","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2025.114268_b0030","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2310960","article-title":"Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China","volume":"29","author":"Ding","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2025.114268_b0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2025.114268_b0040","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2196482","article-title":"A review of treatment options employed in relapsed\/refractory AML","volume":"28","author":"Mohamed Jiffry","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2025.114268_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.833694","article-title":"Transcriptome-wide analysis of RNA N(6)-methyladenosine modification in adriamycin-resistant acute myeloid leukemia cells","volume":"13","author":"Fang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.intimp.2025.114268_b0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-020-01792-8","article-title":"Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway","volume":"39","author":"Wang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.114268_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107652","article-title":"Targeting DNA methyltransferases for cancer therapy","volume":"151","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.intimp.2025.114268_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00432","article-title":"Intersection of epigenetic and metabolic regulation of histone modifications in acute myeloid leukemia","volume":"9","author":"Dhall","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.114268_b0065","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.2147\/OTT.S200005","article-title":"Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia","volume":"12","author":"Dou","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.intimp.2025.114268_b0070","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20210462","article-title":"Histone deacetylase 10, a potential epigenetic target for therapy","volume":"41","author":"Cheng","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.intimp.2025.114268_b0075","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3748\/wjg.v26.i6.598","article-title":"Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer","volume":"26","author":"Amnekar","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.intimp.2025.114268_b0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.intimp.2025.114268_b0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/cancers16010073","article-title":"Venetoclax: a game changer in the treatment of younger AML patients","volume":"16","author":"Molica","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.114268_b0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ijms25010484","article-title":"Venetoclax and hypomethylating agent combination in myeloid malignancies: mechanisms of synergy and challenges of resistance","volume":"25","author":"Mishra","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.114268_b0095","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.114268_b0100","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.114268_b0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.114268_b0110","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.114268_b0115","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.114268_b0120","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.intimp.2025.114268_b0125","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2025.114268_b0130","first-page":"705","article-title":"[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)]","volume":"44","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.intimp.2025.114268_b0135","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2025.114268_b0140","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.intimp.2025.114268_b0145","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2025.114268_b0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.114268_b0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10147-023-02465-0","article-title":"Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology","volume":"29","author":"Maeda","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.114268_b0160","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2025.114268_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2024.101043","article-title":"Epigenetic modulation of immune cells: mechanisms and implications","volume":"94","author":"Fiordoro","year":"2024","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.intimp.2025.114268_b0170","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.114268_b0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.trecan.2019.05.001","article-title":"Targeting the tumor microenvironment of leukemia and lymphoma","volume":"5","author":"H\u00f6pken","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.intimp.2025.114268_b0180","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ijc.33908","article-title":"Microenvironment and drug resistance in acute myeloid leukemia: do we know enough","volume":"150","author":"Ganesan","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2025.114268_b0185","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1007\/s00277-024-06117-9","article-title":"Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies","volume":"103","author":"Zha","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2025.114268_b0190","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/13880209.2021.1944220","article-title":"PTPRM methylation induced by FN1 promotes the development of glioblastoma by activating STAT3 signalling","volume":"59","author":"Song","year":"2021","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.intimp.2025.114268_b0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41419-020-02826-x","article-title":"High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925002589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925002589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:42:33Z","timestamp":1741254153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925002589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":39,"alternative-id":["S1567576925002589"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114268","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114268"}}